Baiji China responds to Aberdeen's patent lawsuit: it will respond and actively defend itself in due course.

[Baiji China responds to Aberdeen's patent lawsuit: it will respond in due time and actively defend] Science and Technology Innovation Board Daily reported on the 15th that according to bloomberg Law, the Pharmacyclics of Baiji Shenzhou accused Baiji Shenzhou's Brukinsa drug (Zebutini) of infringing a patent covering its Imbruvica. Baiji Shenzhou responded to the Science and Technology Innovation Board Daily: "We will respond to the complaint in due course and actively defend it." On the 15th, Baiji Shenzhou An and H shares both fell more than 10%, of which A shares closed down 14%. (reporter Zhu Jie)